Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis

In conclusion, presence of ADA in axial SpA patients treated with adalimumab was associated with lower serum drug levels. ADA levels were lower and adalimumab levels were higher in patients with inactive disease/low disease activity based on BASDAI and ASDAS indices. Concomitant treatment with MTX reduces de likelihood of finding ADA. Serum adalimumab levels above 4.6 mg/l are recommended to avoid compromising efficacy.

Source: Rheumatology International - March 20, 2019 Category: Rheumatology Source Type: research